» Articles » PMID: 32589698

Rosetting T Cells in Hodgkin Lymphoma Are Activated by Immunological Synapse Components HLA Class II and CD58

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2020 Jun 27
PMID 32589698
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

A unique feature of Hodgkin lymphoma (HL) is the presence of CD4+ T cells that surround, protect, and promote survival of tumor cells. The adhesion molecules involved in this so-called T-cell rosetting are important components of the immunological synapse (IS). However, it is unknown whether this synapse is fully assembled and leads to T-cell activation by enabling interaction between the T-cell receptor (TCR) and human leukocyte antigen class II (HLA-II). We established a novel rosetting model by coculturing HLA-II-matched peripheral blood mononuclear cells with HL cell lines and showed IS formation with activation of rosetting T cells. HLA-II downregulation by class II transactivator knockout did not affect the extent of rosetting, but almost completely abrogated T-cell activation. Intriguingly, the level of CD58 expression correlated with the extent of rosette formation, and CD58 knockout or CD2 blockade reduced both rosette formation and T-cell activation. The extension of our findings to primary HL tissue by immunohistochemistry and proximity ligation assays showed interaction of CD2 with CD58 and of TCR-associated CD4 with HLA-II. In conclusion, T-cell rosetting in HL is established by formation of the IS, and activation of rosetting T cells critically depends on the interaction of both TCR-HLA-II and CD2-CD58.

Citing Articles

Cancer ATF4-mediated CD58 endocytosis impairs anti-tumor immunity and immunotherapy.

Zeng H, Yu J, Wang H, Shen M, Zou X, Zhang Z J Transl Med. 2025; 23(1):225.

PMID: 40001116 PMC: 11863482. DOI: 10.1186/s12967-025-06245-4.


Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2.

Jo Y, Sim H, Yun B, Park Y, Jin H Exp Mol Med. 2024; 56(10):2113-2126.

PMID: 39349829 PMC: 11541569. DOI: 10.1038/s12276-024-01317-9.


Implicit Flow Cytometric Diagnosis of Classic Hodgkin Lymphoma Using CD3CD4CD26 T-Cells.

Gravenmier C, Song J, Shao H J Clin Lab Anal. 2024; 38(17-18):e25096.

PMID: 39235202 PMC: 11484709. DOI: 10.1002/jcla.25096.


Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.

Gunawardana J, Law S, Sabdia M, Fennell E, Hennessy A, Leahy C Am J Hematol. 2024; 99(11):2096-2107.

PMID: 39152767 PMC: 11469944. DOI: 10.1002/ajh.27459.


HIV infection is associated with compromised tumor microenvironment adaptive immune reactivity in Hodgkin lymphoma.

Chantziou A, Brenna C, Ioannidou K, Chen O, Korkolopoulou P, Antoniadou A Blood Adv. 2024; 8(24):6215-6231.

PMID: 39116294 PMC: 11697195. DOI: 10.1182/bloodadvances.2023012116.


References
1.
Zaru R, Cameron T, Stern L, Muller S, Valitutti S . Cutting edge: TCR engagement and triggering in the absence of large-scale molecular segregation at the T cell-APC contact site. J Immunol. 2002; 168(9):4287-91. DOI: 10.4049/jimmunol.168.9.4287. View

2.
Dustin M, Olszowy M, Holdorf A, Li J, Bromley S, Desai N . A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell. 1998; 94(5):667-77. DOI: 10.1016/s0092-8674(00)81608-6. View

3.
Liang W, Vergilio J, Salhia B, Huang H, Oki Y, Garrido-Laguna I . Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. Oncologist. 2018; 24(2):219-228. PMC: 6369943. DOI: 10.1634/theoncologist.2018-0058. View

4.
Liu Y, Abdul Razak F, Terpstra M, Chan F, Saber A, Nijland M . The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing. Leukemia. 2014; 28(11):2248-51. DOI: 10.1038/leu.2014.201. View

5.
Diepstra A, van Imhoff G, Karim-Kos H, van den Berg A, Meerman G, Niens M . HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol. 2007; 25(21):3101-8. DOI: 10.1200/JCO.2006.10.0917. View